Cunningham, Richard Anthony 4

4 · TYME TECHNOLOGIES, INC. · Filed Sep 16, 2022

Form 4

Period: 2022-09-16

DirectorChief Executive Officer

Transactions

Disposition to Issuer
Employee Stock Option - Option to buy
2022-09-16−2,000,000→ 0 total
Exercise: $1.03Exp: 2030-11-24→ Common Stock (2,000,000 underlying)
Disposition to Issuer
Employee Stock Option - Option to buy
2022-09-16−500,000→ 0 total
Exercise: $1.43Exp: 2031-06-13→ Common Stock (500,000 underlying)
Disposition to Issuer
Employee Stock Option - Option to buy
2022-09-16−1,326,000→ 0 total
Exercise: $0.33Exp: 2032-04-24→ Common Stock (1,326,000 underlying)

Footnotes (3)

[F1]This option was fully vested and assumed by Syros Pharmaceuticals, Inc. ("Syros") in its merger with the issuer and replaced with an option to purchase 87,640 shares of Syros common stock for $23.51 per share, after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split").
[F2]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 21,910 shares of Syros common stock for $32.63 per share, after giving effect to the Reverse Split.
[F3]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 58,105 shares of Syros common stock for $7.53 per share, after giving effect to the Reverse Split.

Documents

1 file